HD204 vs HLX04

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

HD204

Developed by Intas Pharmaceuticals and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03390686 · Phase 3 · active, not recruiting

This was a randomised, double-blind, active-controlled Phase 3 equivalence trial (625 patients randomised, per the sponsor) comparing HD204 with reference bevacizumab (Avastin), each with chemotherapy, in advanced non-squamous NSCLC. The primary endpoint was objective response rate at week 18, and the prespecified equivalence margin test succeeded (risk ratio 1.047, 95% CI 0.86 to 1.27), showing clinical equivalence with the reference product.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. The sponsor's topline release reports 625 patients randomised 1:1; the registry lists 650 enrolled.

Reported efficacy

Overall Response Rate (ORR) at Week 18 (18 weeks from randomization): SAMSON-II (NCT03390686), primary endpoint ORR at week 18: HD204 48.7% vs reference bevacizumab 46.5%; risk ratio 1.047 (95% CI 0.86-1.27), within prespecified equivalence margin (met)

Result source: NCT03390686

HLX04 · Hanbeitai

Marketed by Shanghai Henlius Biotech

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03952403 · Phase 3 · status unknown

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The first listed primary outcome for this study is Part 1 safety and tolerability; the survival figures shown here are the Part 2 primary endpoint (progression-free survival) and the overall-survival secondary endpoint from the final analysis.

Reported efficacy

Part 1 Safety and tolerability of study treatment (baseline to 21 days); Part 2-Progression Free Survival (PFS) as Determined by the IRRC using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (Baseline until disease progression or death, whichever occurs first (up to approximately 24months)): ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC. (mixed)

Result source: NCT03952403

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHD204HLX04
PFS, median—Trial running · NCT03390686—Not reported
OS, median—Trial running · NCT03390686—Not reported
ORR—Trial running · NCT03390686—Not reported
Duration of response, median—Trial running · NCT03390686—Not reported

PFS, median

HD204
—Trial running · NCT03390686
HLX04
—Not reported

OS, median

HD204
—Trial running · NCT03390686
HLX04
—Not reported

ORR

HD204
—Trial running · NCT03390686
HLX04
—Not reported

Duration of response, median

HD204
—Trial running · NCT03390686
HLX04
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

HD204
SAMSON-II (NCT03390686), primary endpoint ORR at week 18: HD204 48.7% vs reference bevacizumab 46.5%; risk ratio 1.047 (95% CI 0.86-1.27), within prespecified equivalence margin NCT03390686 · Phase 3 · design grade: strong · publication or press release
HLX04
ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC. NCT03952403 · Phase 3 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HD204's landscape · HLX04's landscape